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Abstract
Cyclosporin A (CSA) suppresses immune function by blocking the cyclophilin A and calci-
neurin/NFAT signaling pathways. In addition to immunosuppression, CSA has also been
shown to have a wide range of effects in the cardiovascular system including disruption of
heart valve development, smooth muscle cell proliferation, and angiogenesis inhibition.
Circumstantial evidence has suggested that CSA might control Notch signaling which is
also a potent regulator of cardiovascular function. Therefore, the goal of this project was to
determine if CSA controls Notch and to dissect the molecular mechanism(s) by which CSA
impacts cardiovascular homeostasis. We found that CSA blocked JAG1, but not Dll4 medi-
ated Notch1 NICD cleavage in transfected 293T cells and decreased Notch signaling in
zebrafish embryos. CSA suppression of Notch was linked to cyclophilin A but not calci-
neurin/NFAT inhibition since N-MeVal-4-CsA but not FK506 decreased Notch1 NICD
cleavage. To examine the effect of CSA on vascular development and function, double
transgenic Fli1-GFP/Gata1-RFP zebrafish embryos were treated with CSA and monitored
for vasculogenesis, angiogenesis, and overall cardiovascular function. Vascular patterning
was not obviously impacted by CSA treatment and contrary to the anti-angiogenic activity
ascribed to CSA, angiogenic sprouting of ISV vessels was normal in CSA treated embryos.
Most strikingly, CSA treated embryos exhibited a progressive decline in blood flow that was
associated with eventual collapse of vascular luminal structures. Vascular collapse in zeb-
rafish embryos was partially rescued by global Notch inhibition with DAPT suggesting that
disruption of normal Notch signaling by CSA may be linked to vascular collapse. However,
multiple signaling pathways likely cause the vascular collapse phenotype since both cyclo-
philin A and calcineurin/NFAT were required for normal vascular function. Collectively,
these results show that CSA is a novel inhibitor of Notch signaling and vascular function in
zebrafish embryos.
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Introduction
Cyclosporin A (CSA) is an immunosuppressant that binds to and suppresses cyclophilin A [1].
CSA binding to cyclophilin A not only inactivates cyclophilin A and other cyclophilin family
members, but the cyclophilin/CSA complex also suppresses the calcineurin/NFAT signaling
pathway [2]. Since calcineurin/NFAT signaling is important for the transcription of IL-2 and
other pro-inflammatory proteins, it is via this mechanism that CSA gains its immunosuppres-
sant activity [3, 4]. In addition to the cyclophilin A—NFAT/calcineurin signaling cascade, ad-
ditional evidence also suggests that CSA may interact with the Notch signaling pathway. For
example, in endothelial cells treated with CSA the Notch responsive HESR1 (Hey1) gene was
increased more than any other analyzed gene [5]. Further evidence is provided by Mammucari
et al who have discovered that integration of the Notch and NFAT/calcineurin signaling path-
ways seems to be important for keratinocyte differentiation [6] and Zanotti et al who have
identified Notch and NFAT signaling as reciprocally inhibiting pathways that together regulate
osteoblast function [7].
In addition to immunosuppression, CSA has also been shown to elicit a wide range of nega-
tive effects in the cardiovascular system including disruption of heart valve development,
smooth muscle cell proliferation, and angiogenesis inhibition. In particular, CSA suppress an-
giogenesis in a variety of models including the chick CAM [8, 9], rat mesenteric-window [10],
transplanted pancreatic islets [11], and finally in HUVEC endothelial cells cultured on Matrigel
[12]. Despite these reports, the molecular mechanism by which CSA suppresses angiogenesis is
poorly defined. Recently however, specific inactivation of calcineurin/NFAT with FK506 has
been shown to suppress angiogenesis [13, 14] suggesting that CSA may block angiogenesis by
indirectly blocking calcineurin activity only after first complexing with cyclophilin A. Contrary
to this idea however, cyclophilin A has also been shown to regulate angiogenesis during inflam-
matory reactions [15] and a non-immunosuppressive analog of CSA (N-MeVal-4-CsA) that
does not block calcineurin activity maintains anti-angiogenic activity suggesting that cyclophi-
lin A rather than NFAT/calcineurin is linked to angiogenesis [16]. Based on these observations,
significant controversy still exists about how CSA manipulates angiogenesis.
The original goal of this research was to investigate the ability of CSA to control Notch sig-
naling, and to determine if CSA suppresses angiogenesis in zebrafish embryos. Our results
show that CSA directly suppresses Notch signaling in response to Jagged1 but not Delta-like
4 and that CSA inhibition of cyclophilin A, but not calcineurin is linked to Notch inhibition.
However, CSA did not appear to have a direct effect on angiogenesis in zebrafish embryos, but
rather had widespread negative effects on cardiovascular function that were initiated by inhibi-
tion of both cyclophilin A and calcineurin.
Results and Discussion
CSA suppresses Notch signaling
Previous results have suggested that CSA may interact with the Notch signaling pathway [5] al-
though a molecular analysis of this interaction has not been performed. CSA is known to sup-
press signaling through the calcineurin/NFAT pathway [1] and interestingly, results from
multiple labs suggests a functional association between calcineurin/NFAT and Notch [6, 7].
Based on these observations, we sought to determine if CSA controls Notch signaling. 293T
cells were transfected with Myc-tagged versions of cDNAs encoding the murine Notch1 recep-
tor either alone or in combination with the Notch ligands Jagged1 (JAG1) or Delta-like 4
(Dll4). Cyclosporine was applied 24 hours after transfection and Notch activation was moni-
tored after overnight incubation by western blot analysis with antibodies that specifically
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detected the epitope generated by cleavage of Notch1 at Val1744 during the production of the
active Notch1 N1ICD fragment. As shown in Fig. 1A, N1ICD levels were minimal in the ab-
sence of transfected Notch ligand and co-transfection with JAG1 or Dll4 successfully activated
N1ICD cleavage above background levels. Interestingly, application of CSA blunted Notch
N1ICD generation by JAG1 but not by Dll4. To confirm that CSA did not affect transfection ef-
ficiency or cDNA expression, we stripped the membranes and reblotted with anti-myc anti-
bodies to detect myc-tags on the transfected Notch, JAG1, and Dll4 cDNAs. To control for
differences in protein loading, equal volumes of cell lysates were blotted with anti β-actin anti-
bodies. Fig. 1B summarizes this data by comparing N1ICD levels in cells transfected with
Notch1 alone to cells transfected with combinations of Notch and JAG1 or Dll4 in the presence
or absence of CSA treatment. Western blot data was quantified by densitometry, normalized to
β-actin signal, and statistical analysis of the resulting data demonstrated that the CSA mediated
decrease in JAG1—Notch signaling was significantly decreased while Dll4—Notch signaling
was not significantly affected (Fig. 1B). These results indicated that CSA specifically blocks
JAG1 but not Dll4 mediated N1ICD cleavage. The mechanistic basis for this observation is un-
known, but these results argued against a mechanism involving differential expression of JAG1
or Dll4 protein. Instead, CSA could achieve this activity by modification of JAG1 or Dll4 ligand
affinity for the Notch1 receptor, trafficking of JAG1 or Dll4 to the cell membrane, or one of
several regulatory steps that control NICD accumulation in cells [17]. Finally, it will be interest-
ing to determine if CSA also controls the activation of other Notch receptors such as Notch 3
that play important roles in vascular smooth muscle [18] and pericytes [19].
These results suggested that CSA decreases Notch signaling in transfected 293T cells, but it
was important to determine if CSA also controls Notch signaling in vivo. To accomplish this,
we monitored the affect of CSA on Notch activity in transgenic zebrafish expressing GFP from
the Notch responsive TP1 element (i.e. Tp1bglob:eGFP) as previously described [20]. Freshly
laid Zebrafish embryos were incubated in either 10μMCSA, an equivalent volume of DMSO,
or 15μM gamma-secretase/Notch inhibitor DAPT as a positive control for reduced Notch sig-
naling. After 24 hours, Notch activity in control and treated embryos was compared by mea-
suring GFP fluorescence in a 96-well plate reader. Age matched non-fluorescent zebrafish
embryos were also measured to establish a baseline of non-specific background fluorescence.
As shown in Fig. 1C, both DAPT and CSA decreased GFP fluorescence indicating that both
drugs suppressed Notch signaling. To visually confirm these results, fluorescence microscopy
was used to qualitatively compare whole body GFP fluorescence in control, DAPT, or CSA
treated embryos. As shown in Fig. 1D, compared to untreated embryos, there was a dramatic
decrease in whole body GFP fluorescence in CSA and DAPT treated embryos. Collectively,
these results demonstrated that CSA decreases Notch signaling both in vitro and in vivo.
Cyclophilin A but not Calcineurin/NFAT controls Notch signaling
Binding of CSA to cyclophilin A not only inactivates cyclophilin A, but also forms a CSA/
cyclophilin A complex that subsequently deactivates calcineurin/NFAT function [2]. Since
CSA suppresses activity of both cyclophilin A and calcineurin/NFAT, it was important to de-
termine which pathway was functionally linked to CSA mediated Notch suppression. To ac-
complish this, we compared the Notch suppressing activity of the CSA analog N-MeVal-4-CsA
which blocks cyclophilin A but not calcineurin/NFAT signaling [16], and tacrolimis (FK506)
which inhibits calcineurin/NFAT but not cyclophilin A. 293T cells were again transfected with
combinations of Notch1 and JAG1 then treated with solutions of 10μMCSA, 10μMCSA-ana-
log, or 2μM FK506. As shown in Fig. 2A CSA-analog was able to suppress Notch-Jagged signal-
ing in a similar manner to CSA, while FK506 was unable to block N1ICD accumulation. To
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Fig 1. CSA blocks Notch signaling. (A) Effect of CSA on Notch signaling in vitro. 293T cells were transfected with various combinations of myc-tagged
murine Notch1 (N), JAG1 (J), or Delta-like 4 (D) and treated with either 0.1% DMSO or 10μMCSA.Whole cell lysates were fractionated through SDS-PAGE
gels and western blotted with anti-Val1744 antibody to detect cleaved Notch1 NICD fragments (N1ICD). Stripped blots were re-blotted with β-actin or 9E10
anti-myc antibodies to control for protein loading and expression of various transfected cDNAs. Shown are representative western blots from a single
experiment that was performed five times in its entirety. (B) Western blot quantitation comparing N1ICD levels in cells transfected with Notch1 alone to cells
transfected with combinations of Notch and JAG1 or Dll4 in the presence or absence of CSA. Displayed data represent the mean +/− SE of five individual
experiments. P-values were calculated with the Student’s t-test. (C) Effects of CSA on Notch activity in vivo. Tp1bglob:eGFP embryos which express GFP
from a tandem array of 12 Notch responsive RBP-Jk binding sites were incubated in either 0.1% DMSO, 10μMDAPT, or 10μMCSA. 48 hours later, GFP
signal intensity was quantified in whole, live embryos. Data shown represents the mean +/− SE of 4 individual experiments. P-values were determined by
student’s t-test. (D) Representative pictures of Tp1bglob:eGFP zebrafish embryos incubated with 10M DAPT or 10M CSA and imaged by
fluorescent microscopy.
doi:10.1371/journal.pone.0119279.g001
Cyclosporin-A Controls Vascular LumenMaintenance
PLOS ONE | DOI:10.1371/journal.pone.0119279 March 16, 2015 4 / 13
control for differences in protein loading, the membrane was stripped and reblotted with anti-
vinculin antibodies. To ensure equivalent expression of transfected Notch1 and JAG1 cDNA,
membranes were stripped and reblotted with anti-Myc 9E10 antibodies to detect myc tags ap-
pended to the C-terminal of these proteins. Western blot data was quantified by densitometry,
normalized to vinculin signal, and statistical analysis of the resulting data supported our con-
clusion that CSA and N-MeVal-4-CsA decreased JAG1—Notch signaling while FK506 did not
significantly effect Notch signaling (Fig. 2B). The fact that CSA-analog, but not FK506 blocked
JAG1—Notch1 signaling supported the idea that cyclophilin A, but not calcineurin/NFAT con-
trols Notch signaling which is consistent with results from Shaw et al [5] showing that CSA but
not FK506 controls HesR1 gene expression. This result however is inconsistent with other re-
sults [6, 7] that established connections between calcineurin/NFAT and Notch. Finally, al-
though these experiments do not address the molecular mechanism whereby cyclophilin A
controls Notch, it is interesting to note that prolyl isomerase activity helps fold the ankyrin do-
main of Notch NICD [21] and cyclophilin A (a prolyl isomerase) has been shown to accelerate
folding of the ankyrin domain [22]. Moreover, another prolyl isomerase, PIN1 directly inter-
acts with the NICD domain of Notch and regulates NICD cleavage and activation [23]. There-
fore, it is tempting to speculate that inhibition of cyclophilin A (but not calcineurin/NFAT)
may decrease NICD processing by interfering with NICD folding and processing.
Fig 2. Inhibition of cyclophilin A but not calcineurin/NFAT reduces Notch signaling in 293T cells. (A) Effect of cyclophilin inhibition with N-MeVal-4-
CsA analog, and calcineurin inhibition with FK506 on Notch signaling in 293T cells. 293T cells were transfected with either Notch1 (N) cDNA alone or Notch1
and JAG1 (NJ). The following day cells were treated with either 0.1% DMSO, 10μMCSA, 10μMN-MeVal-4-CsA (Ana), or 2μM FK506 for 24 hours. Whole
cell lysates were fractionated through SDS-PAGE gels and blotted with anti-VAL1744 antibodies to detect cleaved Notch1 NICD fragment (N1ICD). Protein
loading was monitored by stripping and reblotting membranes with anti-vinculin antibodies and equivalent cDNA expression was confirmed by reblotting with
anti-Myc 9E10 antibodies. Shown is a representative result from experiments that were performed four times in their entirety. (B). Western blot quantitation
comparing N1ICD levels in cells transfected with Notch1 alone to cells transfected with Notch1 and JAG1 in the presence or absence of CSA, N-MeVal-4-
CsA, or FK506. Data shown represent the mean +/− SE of four experiments. P-values were determined using the Student’s t-test.
doi:10.1371/journal.pone.0119279.g002
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CSA causes vascular malfunction in zebrafish embryos
CSA treatment elicits a wide variety of effects on endothelial and smooth muscle cells in the
vascular tree. Notch signaling has emerged as a major regulator in the vertebrate vascular sys-
tem, serving roles in both endothelial (i.e. angiogenesis) and smooth muscle cells [24]. Given
our results showing that CSA suppresses Notch signaling and the importance of Notch to vas-
cular function, we set out to observe the effect of CSA treatment on angiogenesis and vascular
function in zebrafish embryos. Freshly laid double transgenic Fli1-GFP / Gata1-RFP zebrafish
embryos were incubated in solutions of 2–10 μMCSA, or DMSO vehicle for 1 to 4 dpf (days
post fertilization). Vascular development was monitored by GFP imaging of endothelium
while vascular function was monitored by RFP imaging of circulating blood cells in treated and
control embryos. There were no obvious developmental defects in body morphology caused by
10μMCSA at any point from 1 to 4 dpf (Fig. 3A-C). Development of the aorta and cardinal
vein also appeared normal after one day of CSA treatment (Fig. 3A). Contrary to the reported
anti-angiogenic activity of CSA, initial sprouting of intersegmental vessels (ISV) from the aorta
(Fig. 3A) was unaffected by 1 day of CSA treatment and the anastomosis of ISV vessels to form
the dorsal lateral anastomotic vessel (DLAV) was also unaffected by CSA treatment after 2
days (Fig. 3B). Overall vascular patterning appeared normal in 2 dpf embryos (Fig. 3B GFP-
low). However, while CSA treated embryos initially did have circulating blood cells and lumen
structures, high power imaging of ISV vessels in embryos treated with CSA for 2 days revealed
a progressive loss of luminal structure (Fig. 3B GFP-high) that was accompanied by a progres-
sive loss of blood flow in ISV and aortic vessels and blood pooling near the heart (Fig. 3B RFP).
Interestingly, CSA treatment of 2 dpf embryos with normal heart function and blood circula-
tion also caused luminal collapse and loss of blood flow suggesting that the effect of CSA on
vessel function may not be linked to initial heart development nor initial vascular development
in the presence of CSA (data not shown). By 4 dpf, luminal structures in CSA treated zebrafish
had collapsed entirely and blood flow was non-existent (Fig. 3C).
Collectively, these results showed that CSA does not appear to affect vasculogenesis or an-
giogenesis in zebrafish embryos since overall patterning and ISV sprouting was indistinguish-
able from control embryos. This is contradictory to several reports indicating that CSA is a
negative regulator of angiogenesis [8, 10, 12, 16, 25]. However, these results do indicate that
CSA has a major effect on subsequent maintenance of the vascular system. Unfortunately,
these experiments did not have the power to dissect the ultimate cause of this dysfunction. In-
deed, since Notch, cyclophilin A, and calcineurin/NFAT are involved in many aspects of the
vascular system such as heart valve formation, lumen development/maintenance, and smooth
muscle function, the observed vascular phenotype could be caused by disruption of any of
these ubiquitous signaling mechanisms and lead to malfunction in a multitude of ways.
Cyclophilin A and NFAT/calcineurin are both required for vascular
function in zebrafish
Previous results have shown that signaling through the calcineurin/NFAT pathway is required
for endothelial response to VEGF [26], and for the normal development of smooth muscle cells
and heart valves [27, 28]. Independently however, cyclophilin A has also been implicated in an-
giogenesis [16], regulation of VEGF signaling [29], and the development of smooth muscle
cells and heart valves [15]. Since CSA suppresses both the calcineurin/NFAT and cyclophilin A
signaling pathways, we attempted to discriminate which of these signaling pathways was linked
to CSA induced vascular dysfunction. Freshly laid zebrafish embryos were treated with 1 to
10μM concentrations of FK506 to specifically inhibit calcineurin/NFAT and monitored for
vascular collapse and loss of blood flow as before. Treatment of zebrafish embryos with 2μM or
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greater solutions of FK506 triggered a loss of blood flow through ISV and aortic vessels similar
to 10 μMCSA treatment (Fig. 4). Specific inhibition of cyclophilin A with N-MeVal-4-CsA
also caused a loss of vascular lumen structures and blood flow although 4-fold more (i.e.
40 μM) CSA analog was required for this effect.
These results suggested that both the calcineurin/NFAT and cyclophilin A pathways are re-
quired for proper maintenance of vascular lumen structures. Although both cyclophilin A
and calcineurin/NFAT have been functionally linked to VEGF signaling in endothelial cells
Fig 3. Cyclosporin-A destabilizes vascular lumen structures in zebrafish embryos. Freshly laid Fli1-GFP/GATA1-RFP zebrafish embryos were
incubated in 10μMCSA or DMSO vehicle control for one, two, or four days. Whole embryo brightfield imaging was used to monitored gross morphology.
Development of the vascular system was monitored by fluorescent microscopy of endothelial specific GFP expression. Circulatory flow was monitored by
fluorescent microscopy of red-blood cell specific RFP expression. (A) Effects of CSA on 1dpf embryos. 1 day after CSA treatment, brightfield imaging of
zebrafish embryos (top panel) was unable to distinguish any significant developmental impact of CSA on gross embryo morphology. Microangiogram
analysis revealed similar development of the primitive vascular system including sprouting intersegmental vessels. (B) Effects of CSA on 2 dpf embryos.
Zebrafish embryos treated with CSA for two days displayed no obvious signs of developmental abnormality in bright field images. Low power GFP imaging
revealed an apparently normal vascular system, however RFP imaging revealed a distinct lack of blood flow throughout the embryo. High power GFP
imaging revealed a lack of vascular lumen structures in ISV structures (arrows). (C) Effect of CSA on 4 dpf embryos. After four days of CSA treatment, no
vascular luminal structures (arrows) or blood flow was evident in CSA treated embryos.
doi:10.1371/journal.pone.0119279.g003
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Fig 4. Inhibition of cyclophilin A or calcineurin/NFAT destabilizes lumen structure. (A) Freshly laid
Fli1-GFP / GATA1-RFP embryos were incubated in 0.1% DMSO, 2μM FK506, or 40μM N-MeVal-4-CsA
Cyclosporin-A Controls Vascular LumenMaintenance
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[26, 29], the observed vascular malfunction was not consistent with the effects of VEGF inhibi-
tion in zebrafish embryos. Indeed, treatment of zebrafish embryos with specific VEGF inhibi-
tors including SU5416 [30] or PTK787 [31], or injection of anti-VEGF-A morpholinos [32]
results in a dramatic loss of overall ISV development in zebrafish embryos. In contrast, we
found that ISV vessels initially develop normally in CSA treated fish. Therefore, the phenotype
caused by suppression of VEGF alone is not consistent with our results and suggests that CSA
stimulated vascular dysfunction in zebrafish embryos does not involve inhibition of VEGF
signaling.
Global Notch suppression partially rescues vascular flow and lumen
maintenance
Our results have shown that suppression of either cyclophilin A or calcineurin/NFAT leads to
the vascular malfunction phenotype triggered by CSA treatment of zebrafish embryos. We also
demonstrated that inhibition of cyclophilin A, but not calcineurin/NFAT decreased JAG1 (but
not Dll4) mediated Notch activation in 293T cells. Based on these results, it was not clear if
suppression of Notch was in any way functionally linked to the CSA vascular malfunction and
we therefore attempted to determine if Notch suppression was implicated in this phenotype.
We hypothesized that if the vascular defects were due solely to Notch inhibition, then suppres-
sion of Notch with the gamma secretase inhibitor drug DAPT should recapitulate the vascular
defects induced by CSA treatment. As shown in Fig. 1C-D, 15μMDAPT reduced Notch-de-
pendent GFP expression in zebrafish embryos to a similar level as 10μMCSA but this concen-
tration was less than the 100μM solutions others have used to completely suppress Notch
signaling in zebrafish embryos [20, 33, 34]. Therefore, treatment of zebrafish with this reduced
DAPT concentration more accurately represented Notch suppression by CSA. As shown in
Fig. 5, CSA again induced luminal collapse and a loss of blood flow in 2 dpf zebrafish embryos
while 15μMDAPT alone did not appear to have any noticeable affect on vascular network de-
velopment, lumen stability, or blood circulation. Thus, it did not appear that vascular dysfunc-
tion in CSA treated embryos was linked to simple Notch inhibition. However, bulk Notch
activity alone is insufficient for proper vascular function. Instead, a balanced input from multi-
ple Notch ligands such as JAG1 and Dll4 is critical for normal angiogenesis and vascular lumen
formation [35]. Given that our earlier results suggested that CSA suppresses JAG1 but not
Dll4, we hypothesized that CSA may disrupt vascular lumen maintenance by favoring Dll4
over JAG1 Notch signaling. Ideally, overexpression of JAG1 might have been used in an at-
tempt to rescue the CSA induced vascular phenotype. However, given that our results in Fig. 2
suggested that CSA does not affect JAG1 expression, this approach did not seem appropriate.
Instead, we rationalized that application of a low concentration of broad spectrum Notch in-
hibitor such as DAPT, might partially block both Dll4 and JAG1 to re-establish a rebalanced,
albeit reduced activity of Notch signaling, and at least in part rescue luminal collapse and blood
flow in CSA treated embryos. Freshly laid embryos were treated with 10μMCSA and 15μM
DAPT then monitored for vascular collapse and blood flow after 2 days of treatment. As
shown in Fig. 5A, DAPT partially prevented the collapse of vascular lumens and loss of blood
flow in the ISV and aortic vessels of CSA treated fish. This rescue was not permanent however
since fish treated with both CSA and DAPT eventually experienced vascular occlusion similar
to that observed in CSA treated fish. Shown in Fig. 5B is a quantitative analysis of zebrafish
(CSA-Analog) for two days. Fluorescent imaging was used to monitor overall vascular development (GFP)
and blood flow (RFP). Similar to CSA, neither FK506 nor N-MeVal-4-CSA had an impact on gross
morphology or overall vascular development however both drugs blocked blood flow.
doi:10.1371/journal.pone.0119279.g004
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embryos with blood flow through the aorta and at least one ISV vessel after 2 days of CSA,
CSA+DAPT, or DAPT treatment. Interestingly, co-treatment with CSA and DAPT also elicited
a striking curvature of the developing embryos suggesting an overlapping activity between CSA
and Notch signaling. Collectively, these results demonstrated that the simple suppression of
Notch by CSA was not likely to account for the vascular phenotype induced by CSA since
DAPT alone was unable to recapitulate the effects of CSA on vascular function. Instead, these
results suggest a more complex regulation of Notch by CSA that ultimately contributes to vas-
cular malfunction. A more detailed analysis will need to be performed to fully understand
the molecular mechanism by which CSA suppression of Notch contributes to vascular
malfunction.
Materials and Methods
Ethics Statement
All work with zebrafish was approved by IACUC committee at Indiana State University
and Boise State University and performed according to Indiana State University (Protocol
Fig 5. Notch inhibition partially rescues CSA induced vascular malfunction. (A) Effect of CSA and DAPT on vascular function in zebrafish embryos.
Freshly laid Fli1-GFP / GATA1-RFP zebrafish embryos were incubated in 0.1% DMSO (Control), 10μMCSA, 15μMDAPT, or 10μMCSA + 15μMDAPT for 2
days. Bright field imaging revealed no gross morphological abnormalities in either CSA or DAPT treated fish, however CSA + DAPT treated fish experienced
an acute curvature. GFP imaging revealed a lack of lumen structures in the ISV (white arrowheads) and aortic vessels (red arrowheads) of CSA treated fish.
DAPT treated fish displayed normal luminal structure and blood flow. CSA + DAPT treated embryos had luminal structures (arrowheads) and blood flow
similar to control or DAPT alone treated embryos. Shown are representative results from a single experiment that was performed five times in its entirety. (B)
Quantitative analysis of blood flow in zebrafish treated with CSA, DAPT, or CSA + DAPT. Data shown represent the average +/− SE of five individual
experiments. P-values were determined by student’s t-test.
doi:10.1371/journal.pone.0119279.g005
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#11–08–2007:AA) and Boise State University (Protocol # 006-AC13–004) Institutional IACUC
guidelines.
Transgenic Zebrafish
Transgenic (Tg(fli-1:eGFP)/Tg(gata-1:RFP) zebrafish were donated by Stephen C. Ekker
(Mayo Clinic, Rochester MN). Freshly laid eggs were incubated in 10μMCSA, 15μMDAPT, or
an equivalent concentration of DMSO and imaged 24–48 hpf under a fluorescent dissecting
microscope (Nikon). Transgenic Notch reporter zebrafish (Tp1bglob:eGFP) were donated by
Dr. Steven D. Leach (John Hopkins University School of Medicine, Baltimore, MD). Notch ex-
pression was monitored in 24 hpf embryos by measuring GFP fluorescence on a fluorescence
multi-well plate reader.
Cell culture and Transfection
293T Cells were grown in DMEM containing 10% FBS at 37°C with 5% CO2. 293T cells were
transfected with 2μg of cDNAs encoding either myc-tagged Notch1, JAG1, of Dll4. 24 hours
post transfection the cells were treated with either 10μMCSA, 2μM FK506, or 10μMDMSO
and incubated for an additional 24 hours. The following day, cell lysates were prepared in boil-
ing SDS-PAGE loading buffer and equal volumes were run on 10% SDS-PAGE gels.
Western blotting
The VAL1744 polyclonal antibody (Cell Signaling Solutions) was used at a dilution of 1:250 to
detect cleaved Notch1. The 9E10 monoclonal antibody (Santa Cruz) was used at a concentra-
tion of 1:1000 to detect myc-tagged Notch1, JAG1, and Dll4. The β-actin monoclonal antibody
(Santa Cruz) was used at a dilution of 1:1000 to detect β-actin as a loading control. The anti-
vinculin antibody (Santa Cruz) was used at a dilution of 1:1000
Acknowledgments
Members of the Albig lab are thanked for critical reading of the manuscript. A special thank
you to S&T Global for synthesis of N-MeVal-4-CsA and to Jun O Liu (Johns Hopkins) for the
gift of this compound.
Author Contributions
Conceived and designed the experiments: RP ARA. Performed the experiments: RP MAB BAN
ARA. Analyzed the data: RP MAB BAN ARA. Contributed reagents/materials/analysis tools:
BAN ARA. Wrote the paper: RP ARA.
References
1. Clipstone NA, Crabtree GR. Calcineurin is a key signaling enzyme in T lymphocyte activation and the
target of the immunosuppressive drugs cyclosporin A and FK506. Ann N Y Acad Sci. 1993; 696:20–30.
PubMed PMID: PMID: 7509131.
2. Liu J, Farmer JD Jr, LaneWS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target
of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 1991; 66(4):807–15. Epub 1991/09/02.
PubMed PMID: PMID: 1715244.
3. Welte K, Wang CY, Mertelsmann R, Venuta S, Feldman SP, Moore MA. Purification of human interleu-
kin 2 to apparent homogeneity and its molecular heterogeneity. J Exp Med. 1982; 156(2):454–64. Epub
1982/08/01. PubMed PMID: PMID: 6980256; PubMed Central PMCID: PMC2186775.
4. Ruscetti FW, Gallo RC. Human T-lymphocyte growth factor: regulation of growth and function of T lym-
phocytes. Blood. 1981; 57(3):379–94. Epub 1981/03/01. PubMed PMID: PMID: 7006707.
Cyclosporin-A Controls Vascular LumenMaintenance
PLOS ONE | DOI:10.1371/journal.pone.0119279 March 16, 2015 11 / 13
5. Shah G, Middleton FA, Gentile KL, Tripathi S, Bruch D, Maier KG, et al. Cyclosporine inhibition of angio-
genesis involves the transcription factor HESR1. J Surg Res. 2008; 149(2):171–6. PubMed PMID:
PMID: 18694572. doi: 10.1016/j.jss.2008.03.016
6. Mammucari C, Tommasi di Vignano A, Sharov AA, Neilson J, Havrda MC, Roop DR, et al. Integration
of Notch 1 and calcineurin/NFAT signaling pathways in keratinocyte growth and differentiation control.
Dev Cell. 2005; 8(5):665–76. PubMed PMID: PMID: 15866158.
7. Zanotti S, Smerdel-Ramoya A, Canalis E. Reciprocal regulation of Notch and nuclear factor of activated
T-cells (NFAT) c1 transactivation in osteoblasts. J Biol Chem. 2011; 286(6):4576–88. PubMed PMID:
PMID: 21131365. doi: 10.1074/jbc.M110.161893
8. Iurlaro M, Vacca A, Minischetti M, Ribatti D, Pellegrino A, Sardanelli A, et al. Antiangiogenesis by cyclo-
sporine. Exp Hematol. 1998; 26(13):1215–22. PubMed PMID: PMID: 9845377.
9. Ribatti D, Vacca A, Cantatore FP, Ria R, Benagiano V, Roncali L, et al. An experimental study in the
chick embryo chorioallantoic membrane of the anti-angiogenic activity of cyclosporine in rheumatoid ar-
thritis versus osteoarthritis. InflammRes. 2000; 49(8):418–23. PubMed PMID: PMID: 11028759.
10. Norrby K. Cyclosporine is angiostatic. Experientia. 1992; 48(11–12):1135–8. PubMed PMID: PMID:
1282107.
11. Vajkoczy P, Vollmar B, Wolf B, Menger MD. Effects of cyclosporine A on the process of vascularization
of freely transplanted islets of Langerhans. J Mol Med (Berl). 1999; 77(1):111–4. PubMed PMID: PMID:
9930941.
12. Nacev BA, Liu JO. Synergistic inhibition of endothelial cell proliferation, tube formation, and sprouting
by cyclosporin A and itraconazole. PLoS One. 2011; 6(9):e24793. PubMed PMID: PMID: 21969860.
doi: 10.1371/journal.pone.0024793
13. Courtwright A, Siamakpour-Reihani S, Arbiser JL, Banet N, Hilliard E, Fried L, et al. Secreted frizzle-re-
lated protein 2 stimulates angiogenesis via a calcineurin/NFAT signaling pathway. Cancer Res. 2009;
69(11):4621–8. PubMed PMID: PMID: 19458075. doi: 10.1158/0008-5472.CAN-08-3402
14. Siamakpour-Reihani S, Caster J, Bandhu Nepal D, Courtwright A, Hilliard E, Usary J, et al. The role of
calcineurin/NFAT in SFRP2 induced angiogenesis—a rationale for breast cancer treatment with the
calcineurin inhibitor tacrolimus. PLoS One. 2011; 6(6):e20412. PubMed PMID: PMID: 21673995. doi:
10.1371/journal.pone.0020412
15. Kim SH, Lessner SM, Sakurai Y, Galis ZS. Cyclophilin A as a novel biphasic mediator of endothelial ac-
tivation and dysfunction. Am J Pathol. 2004; 164(5):1567–74. PubMed PMID: PMID: 15111303.
16. Nacev BA, LowWK, Huang Z, Su TT, Su Z, Alkuraya H, et al. A calcineurin-independent mechanism of
angiogenesis inhibition by a nonimmunosuppressive cyclosporin A analog. J Pharmacol Exp Ther.
2011; 338(2):466–75. PubMed PMID: PMID: 21562139. doi: 10.1124/jpet.111.180851
17. Kadesch T. Notch signaling: the demise of elegant simplicity. Curr Opin Genet Dev. 2004; 14(5):506–
12. PubMed PMID: PMID: 15380241.
18. Ruchoux MM, Domenga V, Brulin P, Maciazek J, Limol S, Tournier-Lasserve E, et al. Transgenic mice
expressing mutant Notch3 develop vascular alterations characteristic of cerebral autosomal dominant
arteriopathy with subcortical infarcts and leukoencephalopathy. Am J Pathol. 2003; 162(1):329–42.
Epub 2003/01/01. doi: 10.1016/S0002–9440(10)63824–2. PubMed PMID: PMID: 12507916; PubMed
Central PMCID: PMC1851116.
19. Wang Y, Pan L, Moens CB, Appel B. Notch3 establishes brain vascular integrity by regulating pericyte
number. Development. 2014; 141(2):307–17. Epub 2013/12/07. doi: 10.1242/dev.096107. PubMed
PMID: PMID: 24306108; PubMed Central PMCID: PMC3879812.
20. Parsons MJ, Pisharath H, Yusuff S, Moore JC, Siekmann AF, Lawson N, et al. Notch-responsive cells
initiate the secondary transition in larval zebrafish pancreas. Mech Dev. 2009; 126(10):898–912.
PubMed PMID: PMID: 19595765. doi: 10.1016/j.mod.2009.07.002
21. Bradley CM, Barrick D. Effect of multiple prolyl isomerization reactions on the stability and folding kinet-
ics of the notch ankyrin domain: experiment and theory. Journal of molecular biology. 2005; 352
(2):253–65. Epub 2005/08/02. doi: 10.1016/j.jmb.2005.06.041. PubMed PMID: PMID: 16054647.
22. Bradley CM, Barrick D. The notch ankyrin domain folds via a discrete, centralized pathway. Structure.
2006; 14(8):1303–12. Epub 2006/08/15. doi: 10.1016/j.str.2006.06.013. PubMed PMID: PMID:
16905104.
23. Rustighi A, Tiberi L, Soldano A, Napoli M, Nuciforo P, Rosato A, et al. The prolyl-isomerase Pin1 is a
Notch1 target that enhances Notch1 activation in cancer. Nat Cell Biol. 2009; 11(2):133–42. Epub
2009/01/20. doi: 10.1038/ncb1822. PubMed PMID: PMID: 19151708.
24. Shawber CJ, Kitajewski J. Notch function in the vasculature: insights from zebrafish, mouse and man.
Bioessays. 2004; 26(3):225–34. PubMed PMID: PMID: 14988924.
Cyclosporin-A Controls Vascular LumenMaintenance
PLOS ONE | DOI:10.1371/journal.pone.0119279 March 16, 2015 12 / 13
25. Rafiee P, Heidemann J, Ogawa H, Johnson NA, Fisher PJ, Li MS, et al. Cyclosporin A differentially in-
hibits multiple steps in VEGF induced angiogenesis in humanmicrovascular endothelial cells through
altered intracellular signaling. Cell Commun Signal. 2004; 2(1):3. PubMed PMID: PMID: 15175101.
26. Zeini M, Hang CT, Lehrer-Graiwer J, Dao T, Zhou B, Chang CP. Spatial and temporal regulation of cor-
onary vessel formation by calcineurin-NFAT signaling. Development. 2009; 136(19):3335–45. PubMed
PMID: PMID: 19710169. doi: 10.1242/dev.037903
27. Beis D, Bartman T, Jin SW, Scott IC, D'Amico LA, Ober EA, et al. Genetic and cellular analyses of zeb-
rafish atrioventricular cushion and valve development. Development. 2005; 132(18):4193–204. Epub
2005/08/19. doi: 10.1242/dev.01970. PubMed PMID: PMID: 16107477.
28. Chang CP, Neilson JR, Bayle JH, Gestwicki JE, Kuo A, Stankunas K, et al. A field of myocardial-endo-
cardial NFAT signaling underlies heart valve morphogenesis. Cell. 2004; 118(5):649–63. Epub 2004/
09/02. doi: 10.1016/j.cell.2004.08.010. PubMed PMID: PMID: 15339668.
29. Alvarez-Arroyo MV, Yague S, Wenger RM, Pereira DS, Jimenez S, Gonzalez-Pacheco FR, et al. Cyclo-
philin-mediated pathways in the effect of cyclosporin A on endothelial cells: role of vascular endothelial
growth factor. Circ Res. 2002; 91(3):202–9. Epub 2002/08/10. PubMed PMID: PMID: 12169645.
30. Cannon JE, Upton PD, Smith JC, Morrell NW. Intersegmental vessel formation in zebrafish: require-
ment for VEGF but not BMP signalling revealed by selective and non-selective BMP antagonists. Br J
Pharmacol. 2010; 161(1):140–9. PubMed PMID: PMID: 20718746. doi: 10.1111/j.1476-5381.2010.
00871.x
31. Chan J, Bayliss PE, Wood JM, Roberts TM. Dissection of angiogenic signaling in zebrafish using a
chemical genetic approach. Cancer Cell. 2002; 1(3):257–67. PubMed PMID: PMID: 12086862.
32. Nasevicius A, Larson J, Ekker SC. Distinct requirements for zebrafish angiogenesis revealed by a
VEGF-A morphant. Yeast. 2000; 17(4):294–301. PubMed PMID: PMID: 11119306.
33. Leslie JD, Ariza-McNaughton L, Bermange AL, McAdow R, Johnson SL, Lewis J. Endothelial signalling
by the Notch ligand Delta-like 4 restricts angiogenesis. Development. 2007; 134(5):839–44. PubMed
PMID: PMID: 17251261.
34. Zecchin E, Filippi A, Biemar F, Tiso N, Pauls S, Ellertsdottir E, et al. Distinct delta and jagged genes
control sequential segregation of pancreatic cell types from precursor pools in zebrafish. Dev Biol.
2007; 301(1):192–204. Epub 2006/10/25. doi: 10.1016/j.ydbio.2006.09.041. PubMed PMID: PMID:
17059815.
35. Alva JA, Iruela-Arispe ML. Notch signaling in vascular morphogenesis. Curr Opin Hematol. 2004; 11
(4):278–83. PubMed PMID: PMID: 15314528.
Cyclosporin-A Controls Vascular LumenMaintenance
PLOS ONE | DOI:10.1371/journal.pone.0119279 March 16, 2015 13 / 13
